Studybox Research

Studybox Research 510(k) studies

510(k) Clinical Studies, Run by a Diagnostics-Only Team.

A 510(k) submission stands or falls on whether the performance data supports substantial equivalence. We design and run the studies that produce that data, using sites already qualified to handle IVD protocols.

Substantial equivalence

510(k) studies

The evidence

Substantial Equivalence, Demonstrated.

A 510(k) argues that your device performs equivalently to a legally marketed predicate. For an in vitro diagnostic, that argument is built from performance data, and the four pillars below are where studies most often succeed or stall.

  1. Clinical Performance

    Sensitivity and specificity against a comparator or clinical reference method, generated in the population the device is intended for.

  2. Analytical Performance

    Precision, reproducibility, detection limits, linearity, interference, and cross-reactivity, typically following CLSI-style designs.

  3. Reproducibility

    Consistent results across sites, operators, days, and lots. Commonly structured across three or more sites to show the device travels.

  4. Intended Use Population

    Prospectively collected specimens from real patients presenting with the relevant signs and symptoms, not banked convenience samples alone.

Where timelines actually go

The Study Isn't Slow. Site Startup Is.

Most 510(k) programs do not lose months to enrollment. They lose them before enrollment starts, qualifying sites that have never run an IVD protocol, negotiating budgets and contracts one at a time, and waiting on IRB submissions that could have been anticipated.

Studybox maintains a network of over 100 pre-qualified sites across point-of-care, urgent care, and home-use settings, already contracted and already familiar with diagnostic protocols. Because qualification happened before your study existed, activation typically takes about four weeks instead of the three to six months a cold site network requires.

  • Sites matched to your intended use profile, not just availability.
  • Geographic and demographic diversity to satisfy FDA expectations.
  • No study-specific qualification visits before you can start.
  • One sponsor contract covering both CRO services and site access.

How we run it

Predicate to Clearance.

One team, one point of contact, no handoffs between a CRO and a separate site organization.

  1. Predicate and Pathway Review

    We confirm the predicate strategy and the evidence FDA will expect before a protocol is written, so the study is designed against the actual submission.

  2. Protocol Design

    Endpoints, comparator method, sample size, and enrollment criteria built to support a substantial equivalence argument.

  3. Site Matching

    Sites selected against the intended use profile and geographic diversity requirements, drawn from a pre-qualified network.

  4. Enrollment and Execution

    Supply management, coordinator support, and site oversight run under one team with a single point of contact.

  5. Monitoring and Data

    Live data review, QA, and deviation management, so problems surface during the study rather than at lock.

  6. Submission Support

    Statistical analysis, clinical study report, and support responding to FDA questions through to clearance.

FAQ

510(k) Questions We Get Often.

01 Does every IVD 510(k) need a clinical study?

No. The evidence FDA expects depends on the device, its predicate, and its intended use. Some submissions are supported largely by analytical data, while others require prospective clinical performance data in the intended use population. The predicate and intended use should be settled before the study is designed.

02 How many sites does a 510(k) study need?

It depends on the device and the claims, but reproducibility work is commonly structured across three or more sites, and clinical performance studies often need multiple geographically diverse sites to capture a representative population. We match site count and location to the specific submission rather than applying a fixed template.

03 Can you use banked or retrospective specimens?

Sometimes, particularly for analytical work or rare conditions. Clinical performance claims usually need prospectively collected specimens from patients in the intended use population. We run both prospective study collection and standing specimen collection under a pre-approved IRB protocol.

04 How long does a 510(k) clinical study take?

Timelines depend on device complexity, enrollment requirements, and seasonality of the target condition. Because our sites are pre-qualified for IVD protocols, activation typically takes about four weeks rather than the three to six months a study-specific qualification cycle usually requires.

05 Do you support Dual Submission for 510(k) and CLIA Waiver together?

Yes. If the device is intended for waived settings, running a Dual Submission study is usually more efficient than clearing the 510(k) first and pursuing a waiver afterwards. See our Dual Submission page for how the combined design works.

Case studies

510(k) Studies Behind Real Clearances.

Real studies from FDA decision summaries. Sponsors stay confidential.

All case studies

  1. No. 01

    510(k), OTC lay-user · Infectious disease

    510(k) Clinical Study for an Over-the-Counter COVID-19 Antigen Home Test

    What the study had to show
    Lay users aged 14 and up had to self-sample, run and read the test with only the labeling, in a home-like setting at about 10 sites.
    Result
    510(k) cleared for home use: about 97% PPA and about 98% NPA across about 650 symptomatic subjects.
    Read the study

  2. No. 02

    510(k) · Hematology

    510(k) Multi-Site Method Comparison Study for a Point-of-Care CBC Analyzer with 5-Part Differential

    What the study had to show
    A 20-parameter CBC with 5-part differential, run at the point of care on capillary and venous blood at 2–4 sites.
    Result
    510(k) cleared, with WBC correlation above 0.9 across about 500 specimens.
    Read the study

  3. No. 03

    510(k) · Hematology

    510(k) Method Comparison Study for a Point-of-Care Fingerstick PT/INR System

    What the study had to show
    Fingerstick INR run by healthcare providers at the point of care, across 3–5 intended-use sites.
    Result
    510(k) cleared, with a slope close to 1 against the laboratory reference across about 350 subjects.
    Read the study

Let's talk about your submission

Bring us the predicate. We'll bring the study.

Tell us about your device and intended use, and we'll come back with the study design and site plan within one business day.

Contact us